Download Slide 1

Adis R&D Insight
SLA – Pipeline Town Hall
Ben Weintraub and
Jeff Southwood
May 23, 2017 - USA
WHY ADIS R&D INSIGHT
May 23, 2017 - USA
2
Why? – Experience, Expertise, and Timeliness

Editorial Staff
— 150+ highly qualified (PhD, MD, PharmD) staff in-house
— Average writing experience = 7-10 years (some up to 20 years)
— Expertise across extensive range of therapeutic areas
— Rigorous training program
— Global focus

inThought Team
— 10 years experience covering pharma for Wall Street
— Practicing physicians on staff to provide the clinician’s perspective
— Network of medical experts

Daily updates from company contacts, press releases, international
conferences, company websites, and journals
Comprehensive pipeline of preclinical, clinical, and launched
compounds, updated daily using sources from around the world.
May 23, 2017 - USA
3
Why? – Scientific/Clinical Emphasis

In-depth reviews of launched products and compounds in development
worldwide covering all indications, countries, and phases

Concise summaries of pivotal clinical trials with links to full study profiles
in Adis Clinical Trials Insight

Comprehensive drug development history provides timeline for key events
and milestones throughout the development process

Detailed synopsis of pharmacokinetics, pharmacodynamics, and adverse
events broken out by indication

Global phase of development table documents progress by country/region
Extensively referenced profiles provide a
narrative of each drug’s developmental history.
May 23, 2017 - USA
4
Why? – inThought Commercial Assessments

inThought Approvability Index
— Probability of FDA approval
— Available for all drugs in active clinical development
— Based on specific factors in each phase of clinical development and
benchmarked against historical parameters
— Absolute probability of approval as well as comparison to similar agents

Revenue Forecasts
— Models assess both currently approved and developmental drugs
— Top-down, based on the addressable patient population
— Forecasts seven years in the future and three years in the past
— Models incorporate Wolters Kluwer’s Healthcare Analytics prescription data
Single-source estimates provide a consistent view of
FDA approvability and worldwide revenue potential.
May 23, 2017 - USA
5
Why? – Ease of Use

Intuitive search by name, class, mechanism, organization, development
role, indication, patient segment, phase, and country

Refine search results to include drugs that are only available for
licensing, small molecules, fixed combinations, orphan drugs, fast track
status, biological, in active development

Save searches, send searches, revise searches

Alerts based on saved searches
Gilead Products by Phase
17 Launched
28 Discontinued - Preclinical
12 No
Development
Reported
10 Phase II
May 23, 2017 - USA
6
Why? – Workflow Solution Tools

Create Excel and PowerPoint
tables and graphs from search
results

Export to Excel or HTML

Exported charts have links to
the database that do not
require a password – email to
anyone
Adis R&D Insight: Gilead Pipeline
2
Drug
Synonyms
Ambrisentan
Drug Development Phase
Indication
Phase
Country
BSF 208075
Pulmonary hypertension
Marketed
GSK1325760A
Pulmonary hypertension
Phase III
European Union, Japan,
United Kingdom, USA
Canada, South America
Letairis
Idiopathic pulmonary
fibrosis
Discontinued(III)
Australia, European
Union, Israel, New
Zealand, North America,
Forvade®
Cytomegalovirus
infections
Marketed
GS 504
Polyomavirus infections
Discontinued(III)
Australia, Brazil, Canada,
European Union, New
Zealand, Switzerland,
USA
USA
HPMPC
Herpes simplex virus
infections
Human papillomavirus
Discontinued(II)
Canada, USA
Discontinued(II)
European Union, USA
infectionssarcoma
Kaposi's
Discontinued(II)
USA
Viral infections
Discontinued(II)
USA
Human papillomavirus
infections contagiosum
Molluscum
Discontinued(Clinical)
Belgium
Discontinued(Clinical)
USA
Cancer
Discontinued(Preclinical)
USA
Rheumatic disorders
Discontinued(Preclinical)
Czech Republic
Daunorubicin citrate
liposome injection
DaunoXome®
Kaposi's sarcoma
Marketed
Acute myeloid leukaemia
Discontinued(II)
Australia, Denmark,
Finland, Spain, Sweden,
USA
VS 103
Brain cancer
Discontinued(II)
USA
Breast cancer
Discontinued(II)
USA
Colorectal cancer
Discontinued(II)
USA
Lymphoma
Discontinued(II)
United Kingdom
Multiple myeloma
Discontinued(II)
USA
Non-Hodgkin's lymphoma Discontinued(II)
USA
Ovarian cancer
Discontinued(II)
USA
Prostate cancer
Discontinued(II)
USA
Acute lymphoblastic
leukaemia
Chronic lymphocytic
Discontinued(I)
France
Discontinued(I)
USA
Volibris®
5
Cidofovir
Vistide®
6
Daunorubicin liposomal
leukaemia
May 23, 2017 - USA
7
Why? – Customer Support

Ask-The-Expert service provides complimentary access to our team of
scientific experts, financial analysts, and physician consultants to help
answer your specific questions
May 23, 2017 - USA
8
EMERGING TRENDS
May 23, 2017 - USA
9
Emerging Trends

Pharma is increasing the pace and sophistication of licensing and
acquisitions, driving a need for better information to screen candidates
and more diverse and detailed information about each product

Emerging markets: visibility into India, China, and other emerging
markets are becoming critical

Pharma doesn’t want a data dump…they need a strategic partner who
can synthesize, condense, and summarize all the available information
in a meaningful way that provides insights that are commercially
relevant to their specific business and business issues

Mix of secondary and primary information, mix of facts and opinions
Drug database users want a single source for clinical data summaries,
forecasts, commercial information, and business development solutions.
May 23, 2017 - USA
10
FUTURE DEVELOPMENTS
May 23, 2017 - USA
11
Future Development

Single site source for clinical, commercial, deals, and regulatory

Incorporate other content from within Wolters Kluwer
— Sales and managed care content from Source Healthcare Analytics
— Clinical Trial content from Adis Clinical Trials Insight
— Epidemiology and clinical content from UpToDate
— inThought Research alert content

Partner with 3rd parties for additional commercial content
— Consensus revenue estimates
— Consensus launch dates
— Patent expiry
Building a single source for clinical data summaries, forecasts,
commercial information, and business development solutions.
May 23, 2017 - USA
12